Glaukos Corp (GKOS) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.

Total Cash From Operating Activities Chart for Glaukos Corp

Glaukos Corp (GKOS) operating cash flow for FY2025 was USD -46.3M. Glaukos Corp's operating cash flow moved from USD -20.5M in 2012 to USD -46.3M in 2025 over 13 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$10.55B
Implied Share Price
$178.88
Enterprise Value
$9.34B
Revenue (TTM)
$612.84M
EBITDA
-$37.02M
Profit Margin
-30.69%
Trailing P/E
—
Forward P/E
1666.67
Price/Book (MRQ)
6.33
Price/Sales (TTM)
17.22
EV/EBITDA
-57.89
EV/Revenue
10.80
Dividend Yield
—
Book Value
$11.60
Free Cash Flow (FY2025)
-$54.01M
Free Cash Flow Yield
-0.51%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.